Loading...
Market
Story
Eli Lilly's Zepbound Promising in Phase 3 Sleep Apnea Trials, FDA Submission Planned
Apr 17, 2024, 03:30 PM
Eli Lilly's weight-loss drug, Zepbound, has shown significant promise in treating obstructive sleep apnea, according to results from Phase 3 clinical trials. The drug, which costs about $1,000 a month and is already popular for weight loss, helped reduce episodes of irregular breathing in patients with the sleep-related disorder. This development could make Zepbound the first pharmaceutical treatment specifically approved for obstructive sleep apnea. Eli Lilly plans to submit these findings to the FDA, aiming for an expanded use approval. The company also highlighted that the drug reduced sleep apnea severity by nearly two-thirds in adults.
View original story
Similar markets
Low penetration (<1%) • 25%
Moderate penetration (1-3%) • 25%
High penetration (3-5%) • 25%
Very high penetration (>5%) • 25%
Less than $1 billion • 33%
$1-2 billion • 33%
More than $2 billion • 33%
Under 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Over 75% • 25%
Less than 5% • 33%
5%-10% • 33%
More than 10% • 34%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Above $2 billion • 25%
Less than 5% • 25%
5%-10% • 25%
10%-15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%